Core Insights - The report from CITIC Securities indicates that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1] - It is believed that by 2026, the logic of AI in healthcare will undergo fundamental changes, primarily due to clearer and stronger payment capabilities this year [1] - 2026 is expected to be a year with stronger certainty in the commercialization of AI in healthcare, opening up more opportunities for its commercialization [1] Key Focus Areas - The report suggests focusing on five main areas: AI pharmaceuticals, grassroots AI healthcare applications, medical data circulation and trading, AI pathology diagnosis, AI healthcare models, and C-end expansion channels [1]

Core Viewpoint - The company, Jiewate, has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. The company focuses on the design and development of analog integrated circuits using a virtual IDM model and has developed a proprietary process platform. [1] Company Overview - Jiewate's product portfolio primarily includes power management integrated circuits and signal chain integrated circuits, with approximately 3,400 models available for sale by October 31, 2025. [1] Market Position - In 2024, Jiewate ranks 13th globally among all analog integrated circuit companies in terms of revenue in the Chinese market, holding a market share of 0.9%. [1] - In the power management integrated circuit market, Jiewate ranks 8th globally and 4th in China, with a market share of 1.3%. [1] - In the DC-DC integrated circuit market, the company ranks 6th globally and 2nd in China, with a market share of 1.9%. [1] - In the Chinese communication market for power management integrated circuits, Jiewate ranks 5th globally and 2nd in China, with a market share of 3.0%. [1] - In the Chinese computing and storage market for power management integrated circuits, the company ranks 6th globally and 2nd in China, with a market share of 1.1%. [1] Industry Growth - The global and Chinese integrated circuit markets are experiencing strong growth, driven by factors such as artificial intelligence, automotive electronics, and communication technologies. The market size in China is expected to reach RMB 2.74 trillion by 2029. [1]

Group 1 - The Hong Kong IPO market has started 2026 with strong momentum, with multiple companies successfully completing their IPOs across various sectors, including semiconductors and software services [1][2] - As of January 13, 2026, 11 companies have completed IPOs in Hong Kong, raising a total of HKD 33.1 billion, with significant contributions from the semiconductor and software service industries [2] - In 2025, the Hong Kong IPO market reached a total fundraising amount of HKD 612.4 billion, representing a year-on-year increase of over 250% [2] Group 2 - The refinancing market in Hong Kong also showed robust growth in 2025, with 574 companies involved, marking a 43.5% increase year-on-year, and a total refinancing scale of HKD 326.4 billion, up 278.15% [2][3] - The automotive sector emerged as a key player in refinancing, with major companies like BYD and Xiaomi leading the way [3] Group 3 - Chinese securities firms have established a dominant position in the Hong Kong IPO market, holding six out of the top ten spots in equity underwriting, with a combined market share exceeding 56% [4] - Notable firms such as CICC and CITIC Securities have significantly contributed to the fundraising efforts, with CICC raising HKD 66.2 billion and CITIC Securities raising HKD 48.6 billion [4] Group 4 - The pipeline for IPOs remains strong, with over 300 companies waiting to go public, primarily in the technology and pharmaceutical sectors [7] - The Hong Kong Stock Exchange's recent rule changes are expected to further enhance the market's competitiveness and liquidity, potentially leading to an IPO fundraising scale exceeding HKD 300 billion in 2026 [7] Group 5 - The overall performance of securities firms in 2025 has been bolstered by investment banking activities, with significant revenue growth reported across major firms [6] - CICC and CITIC Securities reported substantial increases in revenue, driven by strong performance in their core business segments [6]

● 本报记者 谭丁豪 2026年伊始，港股市场的IPO进程已在忙碌地进行。 港股一级市场迎来"开门红"，开年不久便有多家企业顺利完成IPO，涵盖半导体、软件服务等多个赛 道，部分企业募资表现亮眼。回望2025年，港股一级市场热度空前，不仅在全球主要交易所中脱颖而 出，而且IPO与再融资市场均展现出强劲活力。 与此同时，中资券商在港股投行市场占据主导地位，凭借扎实的业务能力展现出强劲竞争力，港股投行 业务也成为多家券商母公司业绩增长的重要支撑。 当前，港股市场仍有大批企业排队等待IPO，多家机构表示，得益于港交所持续优化相关上市规则，以 及各类资金的持续流入，2026年港股新股市场有望延续良好势头，市场发展前景值得期待。 11家公司完成上市 今年以来，截至1月13日，港股市场已有11家公司完成IPO上市，主板10家，创业板1家，募资总额达 331亿港元。上市公司分别为壁仞科技、MINIMAX-WP、豪威集团、兆易创新、智谱、天数智芯、瑞博 生物、精锋医疗-B、金浔资源、红星冷链、BBSB INTL。 从行业分类来看，上述11家上市公司中，4家为半导体行业，2家为软件服务行业，其余分别所属医药生 物、医疗设备与服 ...

Group 1 - The A-share market has shown a strong upward trend since the beginning of 2026, with the financing balance of the two markets exceeding 2.6 trillion yuan, prompting leading brokerage firms to issue bonds to support business development [1][3] - Major brokerages have actively engaged in bond issuance, with China Galaxy announcing a public bond issuance of up to 30 billion yuan and East Money Securities planning to issue up to 20 billion yuan in subordinated bonds [1][3] - The bond financing scale for brokerages has experienced explosive growth, with a total issuance amount of 81.3 billion yuan in early 2026, a nearly 70% increase compared to the same period in 2025 [3][4] Group 2 - The surge in bond financing is driven by a combination of factors, including increased market activity, rising capital demands, and a favorable low-interest-rate environment that makes bond financing more attractive than equity financing [6][7] - Brokerages are using the proceeds from bond issuances primarily for replenishing working capital and repaying maturing debts, which is crucial for their operational stability and growth [5][6] - The trend of bond issuance is expected to continue in 2026, with a focus on capital supplement bonds and a shift towards longer-term financing to match the capital needs of margin trading and proprietary investment [8][9]

2026年1月9日，深交所主板上市公司越秀资本（000987.SZ）发布的公告显示，该公司董事长王恕慧先生因工作变动，辞去公司董事长、法定代表 人、董事及董事会专门委员会委员等职务及公司控股子公司相关职务。辞职后，王恕慧先生将不再担任公司及控股子公司任何职务。 值得关注的是，紧接着在1月12日，他还辞去了中信证券非执行董事的职务。这表示，一位身兼两家上市公司职务的金融高管，几乎同一时间于 这两家公司卸任。 早期职业：曾任原广州证券证券发行咨询部业务经理、研究拓展部副经理、董事会秘书、副总裁。 越秀集团任职：此后加入越秀集团，曾任广州越秀集团办公室总经理、发展部总经理，香港越秀总经理助理、董事、副总经理。 越秀资本体系任职：后任越秀资本党委书记、董事长，广州越秀资本控股集团有限公司董事长，广州越秀产业投资有限公司董事长，广州越秀产 业投资基金管理股份有限公司董事。 | 姓名 | 离任职务 | 离任时间 | 原定任期到 | 离任原因 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | | | | | 期日 | | ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——"春节也要加班，抢在4月1日前交货"！有光伏企业在抢出口，也有企业很 纠结：白银等原材料成本激增，决策困难 （记者 王瀚黎） 每经AI快讯，中信证券1月13日晚间发布公告称，截至公告披露日，公司及控股子公司对外担保总额为 人民币2052.01亿元（全部为公司及其控股子公司对其控股子公司提供的担保），占公司最近一期经审 计净资产的比例为70.01%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6030） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中信証券股份有限公司（「本公司」）在上海證券交易所網站刊登的本公司關於間 接子公司發行中期票據並由全資子公司提供擔保的公告，僅供參閱。 承董事會命 中信証券股份有限公司 董事長 張佑君 中國北京 2026年1月13日 於本公告刊發日期 ，本公司執行董事為張佑君先生 、鄒迎光先生及張長義先生；本公司非執行董事為李艺女士 、 梁丹先生、張學軍先生、付臨芳女士及趙先信先生；本公司獨立非執行董事為李青先生、史青春先生、張健華 先生、劉俏先生及李蘭冰女士；及本公司職工董事為施亮先生。 证券代码：600030 证券简称：中信证券 公告编号：临2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 ...

证券代码：600030 证券简称：中信证券 公告编号：临2026-002 中信证券股份有限公司 关于间接子公司发行中期票据 并由全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 本次担保金额 | 实际为其提供的担保余额 | 是否在前期 | 本次担保是 | | --- | --- | --- | --- | --- | --- | --- | | | | | | （不含本次担保金额） | 预计额度内 | 否有反担保 | | CSI MTN | | Limited | 1亿港元 | 28.66亿美元 | 是 | 否 | 1 （二） 内部决策程序 经公司第八届董事会第二十二次会议预审，经公司2023年度股东大会批准并 再次授权公司发行境内外公司债务融资工具。本次担保在上述授权范围之内。 | 被担保人类型 | 法人 | | | | --- | --- | --- | --- | | 被担保人名称 | CSI MTN Limited | | | | ...

Core Viewpoint - Dize Pharmaceutical (688192.SH) has announced a projected net loss for the year 2025, despite an expected significant increase in revenue compared to the previous year. Financial Performance - The company anticipates a revenue of approximately 800 million yuan for 2025, which represents an increase of about 440.1 million yuan or 122.28% year-on-year [1] - The projected net loss attributable to shareholders is around 770 million yuan, a reduction of approximately 75.96 million yuan or 8.98% compared to the previous year [1] - The expected net loss after deducting non-recurring gains and losses is about 850 million yuan, which is a decrease of around 48.89 million yuan or 5.44% year-on-year [1] Historical Financial Data - From 2019 to 2024, the company's revenue figures were 41.02 million yuan, 27.76 million yuan, 10.29 million yuan, 0 yuan, 91.29 million yuan, and 360 million yuan respectively [2] - The net profit attributable to shareholders during the same period was -446 million yuan, -587 million yuan, -670 million yuan, -736 million yuan, -1.108 billion yuan, and -846 million yuan [2] - The net profit after deducting non-recurring gains and losses was -449 million yuan, -393 million yuan, -682 million yuan, -785 million yuan, -1.161 billion yuan, and -899 million yuan [2] - The net cash flow from operating activities was -366 million yuan, -410 million yuan, -492 million yuan, -603 million yuan, -968 million yuan, and -651 million yuan [2] Fundraising Activities - Dize Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, 2021, issuing 40.01 million shares at a price of 52.58 yuan per share [3] - The total amount raised from the initial public offering was 2.103 billion yuan, with a net amount of 1.987 billion yuan after deducting issuance costs [3] - The company raised a total of 3.899 billion yuan from two fundraising activities [5]